Morotti, Matteo http://orcid.org/0000-0002-1790-1185
Albukhari, Ashwag
Alsaadi, Abdulkhaliq
Artibani, Mara
Brenton, James D. http://orcid.org/0000-0002-5738-6683
Curbishley, Stuart M.
Dong, Tao
Dustin, Michael L.
Hu, Zhiyuan
McGranahan, Nicholas
Miller, Martin L. http://orcid.org/0000-0003-3161-8690
Santana-Gonzalez, Laura
Seymour, Leonard W.
Shi, Tingyan
Van Loo, Peter http://orcid.org/0000-0003-0292-1949
Yau, Christopher
White, Helen
Wietek, Nina
Church, David N. http://orcid.org/0000-0002-4617-962X
Wedge, David C. http://orcid.org/0000-0002-7572-3196
Ahmed, Ahmed A.
Funding for this research was provided by:
DH | National Institute for Health Research (RCF18/046)
Ovarian Cancer Action (HER000762)
Article History
Received: 9 November 2020
Revised: 22 February 2021
Accepted: 4 March 2021
First Online: 29 March 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Not applicable.
: J.D.B. has received honoraria from consulting/honoraria with AstraZeneca and GSK, receives research support from Aprea AB and holds equity in Inivata and Tailor Bio. T.D has received honoraria from consulting with Oxford Immunotec Limited. M.L.D. is a scientific advisory board member of Adaptimmune. N.M. has received consultancy fees and has stock options in Achilles Therapeutics. N.M. holds European patents relating to targeting neoantigens (PCT/EP2016/ 059401), identifying patient response to immune checkpoint blockade (PCT/ EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221). M.L.M. has received honoraria from GSK which are not related to this work. L.W.S. is founder, consultant and holds equity in two oncolytic virus companies (Psioxus Therapeutics Ltd and Theolytics Ltd). C.Y. receives enumeration for consultancy for Singula Bio Ltd. D.N.C. is a scientific advisory board member of MSD. A.A.A. is a founder, shareholder and consultant for Singula Bio Ltd. M.M., As.A., Aa.A., M.A., S.M.C., Z.H., L.S.G., T.S., P.V.L., H.W. and N.W. declare no conflict of interest.
: This work was supported by the following grants: Ovarian Cancer Action HER000762 and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre IS-BRC-0211-10025 to A.A.A. NIHR Research Clinical Fellow award RCF18/046 to M.M. T.D. is supported by Medical Research Council, UK and Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant number: 2018-I2M-2-002). N.M. is a Sir Henry Dale Fellow, jointly funded by the Wellcome Trust and the Royal Society (Grant Number 211179/Z/18/Z), and also receives funding from Cancer Research UK Lung Cancer Centre of Excellence, Rosetrees, and the NIHR BRC at University College London Hospitals. P.V.L. is supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001202), the UK Medical Research Council (FC001202), and the Wellcome Trust (FC001202). P.V.L. is a Winton Group Leader in recognition of the Winton Charitable Foundation’s support towards the establishment of The Francis Crick Institute. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health.